#tripleswitch - Twitter Hashtag

zixxi

@Nawmeaner

about 1 month ago

@rikkjamez896 That boy got motion #TripleSwitch

1

5

0

262

Karine Tawagi MD @DrKarineTawagi

5 months ago

mHSPC tx selection by @ChrisSweens1 ✅ ADT + ARPI ➡️ RT for low-vol ❓when to add PARPi, LuPSMA, AKT inh ➡️ Doce to high-volume, ongoing #ASPIRE, #TRIPLESWITCH ‼️pts want tx breaks: De-Escalate, Libertas, A-DREAM ✅ Discuss 🏃🏽‍♀️🦴❤️🧠 ➡️ futuristic trial ph4 trial idea

DrKarineTawagi's tweet photo. mHSPC tx selection by @ChrisSweens1

✅ ADT + ARPI

➡️ RT for low-vol

❓when to add PARPi, LuPSMA, AKT inh

➡️ Doce to high-volume, ongoing #ASPIRE, #TRIPLESWITCH

‼️pts want tx breaks: De-Escalate, Libertas, A-DREAM

✅ Discuss 🏃🏽‍♀️🦴❤️🧠

➡️ futuristic trial ph4 trial idea https://t.co/lYMRWWzDQ9

1

30

13

9

2K

UroToday.com

@urotoday

11 months ago

#TRIPLESWITCH Trial: Intensifying treatment for suboptimal PSA response in #mHSPC. @michael_ong, @sokolova_md & @TDorffOnc join @neerajaiims to discuss on UroToday. This joint CCTG-SWOG phase III trial addresses a critical gap by randomizing 830 patients with suboptimal PSA responses to continue standard ADT + AR pathway inhibitor therapy vs adding six cycles of docetaxel. #WatchNow > https://t.co/mPktP3bEGR

0

15

6

5

2K

UroToday.com

@urotoday

12 months ago

#TRIPLESWITCH Trial: Intensifying treatment for suboptimal PSA response in #mHSPC. @michael_ong, @sokolova_md & @TDorffOnc join @neerajaiims to discuss on UroToday. This joint CCTG-SWOG phase III trial addresses a critical gap by randomizing 830 patients with suboptimal PSA responses to continue standard ADT + AR pathway inhibitor therapy vs adding six cycles of docetaxel. #WatchNow > https://t.co/mPktP3bEGR

0

6

3

4

996

UroToday.com

@urotoday

about 1 year ago

#TRIPLESWITCH Trial: Intensifying treatment for suboptimal PSA response in #mHSPC. @michael_ong, @sokolova_md & @TDorffOnc join @neerajaiims to discuss on UroToday. This joint CCTG-SWOG phase III trial addresses a critical gap by randomizing 830 patients with suboptimal PSA responses to continue standard ADT + AR pathway inhibitor therapy vs adding six cycles of docetaxel. #WatchNow > https://t.co/mPktP3bEGR

2

30

8

15

5K

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang

about 1 year ago

The #IRONMAN registry with some practical updates on PSA response in metastatic hormone sensitive #prostatecancer — depth of PSA response matters — sets up current #TRIPLESWITCH trial in @CDNCancerTrials @SWOG. Congrats @MichaelOng_MD & team. #ASCO25 @urotoday

TiansterZhang's tweet photo. The #IRONMAN registry with some practical updates on PSA response in metastatic hormone sensitive #prostatecancer — depth of PSA response matters — sets up current #TRIPLESWITCH trial in @CDNCancerTrials @SWOG. Congrats @MichaelOng_MD & team. #ASCO25 @urotoday https://t.co/5C03YrzO9G

Neeraj Agarwal, MD, FASCO

@neerajaiims

about 1 year ago

Congrats @MichaelOng_MD for the stellar talk @ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). @OncoAlert @urotoday @PCF_Science @Daniel_J_George

$neerajaiims's tweet photo. Congrats @MichaelOng_MD for the stellar talk @ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). @OncoAlert @urotoday @PCF_Science @Daniel_J_George https://t.co/d2e8E3rJjz$

4

50

27

9

5K

0

14

6

2

2K

Karine Tawagi MD @DrKarineTawagi

about 1 year ago

Proud of my mentor @DrMichaelOng presenting impt international #IRONMAN data: 🚹 mCSPC w/ ADT + ARPI 🌀PSA of >= 0.2 at 6-12mo = worse px (mOS 30mo) ➡️consider #TRIPLESWITCH intensification trial now open 🌀PSA<0.2 at 6-12mo = good px ➡️ consider #DEESCALATE trial #ASCO25

DrKarineTawagi's tweet photo. Proud of my mentor @DrMichaelOng presenting impt international #IRONMAN data:

🚹 mCSPC w/ ADT + ARPI

🌀PSA of >= 0.2 at 6-12mo = worse px (mOS 30mo) ➡️consider #TRIPLESWITCH intensification trial now open

🌀PSA<0.2 at 6-12mo = good px ➡️ consider #DEESCALATE trial

#ASCO25 https://t.co/3dDicZawY3

1

33

10

4

2K

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang

over 1 year ago

@TDorffOnc always thoughtful w discussion for metastatic #prostatecancer — buckets of treatments - doublets, triplets, XRT, including trials! #TRIPLESWITCH, #ADREAM, S1802, and more! @ASCO #GU25

TiansterZhang's tweet photo. @TDorffOnc always thoughtful w discussion for metastatic #prostatecancer — buckets of treatments - doublets, triplets, XRT, including trials! #TRIPLESWITCH, #ADREAM, S1802, and more! @ASCO #GU25 https://t.co/I7JGmx0LWL

1

18

9

1

989

Enrique Corbella 🏀 @ecorbella

over 2 years ago

Vuelve #TripleSwitch con @willy_garcia4 y un servidor hablando de baloncesto y otras cosas de la vida... ¿Te apuntas? https://t.co/2ECnzbaBii

0

4

1

0

682

Enrique Corbella 🏀 @ecorbella

over 2 years ago

Llevaba tiempo queriendo compartir mi participación junto a @willy_garcia4 y @uros_dragicevic en #TripleSwitch hablando, como no, de baloncesto 🏀 . Como se despisten les derroco y les desmonto el chiringuito... https://t.co/fq976dAIKL

0

1

0

950

Jevaughn Pinnock / MOVEMENT SPECIALIST🦶🏽 @JevaughnPinnoc4

over 4 years ago

Switching drills are taught from day 1. Once You Have The “RHYTHM” and the “TIMING” Down, You Must Begin To Apply Faster “THIGH VELOCITIES” To Attack The Ground With “FORCE”. 🧠✍🏽 #Aseries #TripleSwitch #QGTM

0

105

20

24

0

Jevaughn Pinnock / MOVEMENT SPECIALIST🦶🏽 @JevaughnPinnoc4

over 4 years ago

Triple Switch w/ 1 sec Pause Learning to switch your limbs effectively and efficiently is a major KPI to fast sprint times. #TripleSwitch #Aseries #ASwitch